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A B S T R A C T
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are prevalent ailments with a great
challenge to distinguish them based on symptoms only. Since they require different treatments, it is important to
find non-invasive methods capable to readily diagnose them. Moreover, COPD increases the risk of lung cancer
development, leading to their comorbidity. In this pilot study the N-glycosylation profile of pooled human serum
samples (90 patients each) from lung cancer, COPD and comorbidity (LC with COPD) patients were investigated
in comparison to healthy individuals (control) by capillary gel electrophoresis with high sensitivity laser-induced
fluorescence detection. Sample preparation was optimized for human serum samples introducing a new tem-
perature adjusted denaturation protocol to prevent precipitation and increased endoglycosidase digestion time
to assure complete removal of the N-linked carbohydrates. The reproducibility of the optimized method
was< 3.5%. Sixty-one N-glycan structures were identified in the pooled control human serum sample and the
profile was compared to pooled lung cancer, COPD and comorbidity of COPD with lung cancer patient samples.
One important finding was that no other sugar structures were detected in any of the patient groups, only
quantitative differences were observed. Based on this comparative exercise, a panel of 13 N-glycan structures
were identified as potential glycobiomarkers to reveal significant changes (> 33% in relative peak areas) be-
tween the pathological and control samples. In addition to N-glycan profile changes, alterations in the individual
N-glycan subclasses, such as total fucosylation, degree of sialylation and branching may also hold important
glycobiomarker values.
1. Introduction
Lung cancer (LC) is one of the predominantly diagnosed cancers
(11.6% of the total cases) and was the main cause of cancer deaths
(18.4% of the total cancer deaths) in 2018 in both genders combined
[1]. Another prevalent lung disease is Chronic Obstructive Pulmonary
Disease (COPD), mostly caused by cigarette smoking, representing a
great but certainly preventable risk factor [2]. COPD has recently be-
come in the spotlight due to its elevating incidence rate, morbidity,
mortality and increasing the risk of developing lung cancer, in many
cases creating formidable challenges for the global healthcare systems
[3]. Simultaneous diagnoses of LC and COPD (i.e., comorbidity)
represent poor prognosis [2], thus treatments should be planned ac-
cordingly [4]. The high mortality rate of COPD and lung cancer could
be due to the asymptomatic property at their early stages, and the lack
of appropriate distinguishing diagnostic tools. While biopsy can dif-
ferentiate malignant (LC) and benign (inflammation) lesions that ima-
ging techniques are not capable in a reliable diagnostic manner, it is an
invasive process with a number of risk factors including infections,
pneumonia, pneumothorax, bleeding and haemoptysis, just to list the
most frequent ones [5]. Furthermore, another potential drawback of
biopsy is the risk of tumor spreading, i.e., during the biopsy process,
possible metastasis initiating circulating tumor cells may get away from
the primary tumor [6,7]. Therefore, there is an urgent need to develop
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non-invasive molecular diagnostic tools capable of predicting the pre-
sence and prognosis of the actual disease (LC, COPD or comorbidity)
with adequate specificity and sensitivity.
Ever-growing evidence shows the importance of the N-glycosylation
of proteins in biological systems, demonstrating that this post-transla-
tional modification is as essential as the polypeptide backbone itself,
playing significant roles in forming their higher order structure, bio-
chemical properties and function [8]. Suzuki et al. [9] studied the im-
portance and roles of N-glycosylation in COPD and found that the re-
duction of FUT8 activity has close relation with the progression of the
disease. Phillips and coworkers [10] reviewed the glycosylation aspects
of lung cancer and the mechanisms of post-synthetic glycan modifica-
tion during malignant transformation suggesting promising biomarkers
and therapeutic possibilities based on their N-glycosylation alterations.
The significance of these changes revealed that identifying N-glycan
biomarkers as potential early detection markers and monitoring the
treatment of lung diseases [2] can be of high importance. The human
serum contains a plethora of proteins with the majority of them gly-
cosylated [11]. Protein glycosylation is the consequence of very com-
plex biochemical processes, regulated by a number of glycosidases and
glycosyltransferases [9] resulting in diverse but protein specific glycan
profiles, which affect several cellular properties such as signaling, ad-
hesion, motility and half-life, just to mention a few important ones [12].
Genetic and environmental factors can both affect the activity of this
glycosylation machinery that may lead to altered glycan structures,
possibly specific for pathological changes. Comprehensive analysis of
complex carbohydrates requires high sensitivity methods with en-
hanced resolution because of their great structural diversity. The most
frequently applied techniques for N-glycan analysis are high-perfor-
mance liquid chromatography (HPLC), capillary electrophoresis (CE),
mass spectrometry (MS) and NMR, or the combination of those such as
LC-MS or CE-MS [13].
In several cases, N-glycosylation alterations affect the high abun-
dant and acute phase proteins, including immunoglobulin G (IgG)
[14,15], immunoglobulin A (IgA) [11,16,17], alpha-1-antitrypsin
(AAT) [18], haptoglobin (HP) [19,20] and transferrin (TR) [21,22].
Pavić et al [15] analyzed the human plasma and its IgG subset of COPD
patients and healthy controls by UPLC and provided new insights into
plasma protein and IgG N-glycome changes. The plasma protein N-
glycome significantly decreased in low branched type and increased in
more complex glycan structures in COPD patients. Ito et al. investigated
the N-glycans of a lung-specific protein, surfactant protein D, using
matrix-assisted laser desorption/ionization quadrupole ion trap time-of-
flight mass spectrometry and found that the fucosylation level was
greatly elevated in COPD patients compared to controls [23]. Rudd and
coworkers analyzed the serum of lung cancer patients and healthy
controls by high performance hydrophilic interaction liquid chroma-
tography (HILIC) and anion exchange chromatography [24]. They
found that the level of bi- (A2), tri- (A3) and tetra-antennary (A4)
glycans were significantly increased in lung cancer compared to healthy
controls and a reduction was observed in the amounts of core-fucosy-
lated bi-antennary structures. In addition to total human serum, one of
the abundant proteins, haptoglobin was analyzed and similar altera-
tions were found in both sample types. Váradi et al. also studied the
human serum haptoglobin in lung diseases and emphasized the im-
portance of measuring the core- to arm-fucosylation ratios [20]. The
slight decrease in the total fucosylation level of haptoglobin in the
serum of COPD and pneumonia patients compared to the control group
was the result of a significant decrease in arm-fucosylation and a slight
increase in core-fucosylation. Elevated amounts of core- (FA4G4) and
antennary-fucosylated tetra-antennary glycans (A4FG4) in haptoglobin
were also observed comparing lung cancer and COPD patient groups.
Ruhaak et al. investigated the N-glycans of several high abundance
glycoproteins enriched by affinity capture from plasma samples of lung
adenocarcinoma patients as well as healthy controls and analyzed with
nano-HPLC-chip-TOF-MS to search for lung cancer biomarkers [25].
They found that, while the N-glycan profiles of blood-derived glyco-
proteins could be adequate biomarkers for lung cancer, protein en-
richment did not improve specificity, but made the method more
complicated. Liang et al. [18] examined different types of pulmonary
diseases including lung adenocarcinoma, squamous cell lung cancer,
small-cell lung cancer as well as several benign ones, such as pneu-
monia, pulmonary nodule and tuberculous pleuritis and suggested that
the N-glycosylation patterns of α-1-antitrypsin could be a potential lung
cancer biomarker.
In this paper we report on a pilot study of the N-glycosylation
profiles of pooled human serum samples from patients with COPD, lung
cancer and their comorbidities (COPD with LC) compared to control
healthy subjects (pool of 90 patients each) using capillary electro-
phoresis with laser-induced fluorescent detection (CE-LIF). A new
temperature adjusted denaturation protocol was used to prevent pre-
cipitation and the endoglycosidase digestion time was increased to as-
sure full removal of the N-linked oligosaccharides. Sixty-one N-glycans
were identified in the pooled, control human serum samples based on
data in publicly available GU databases and exoglycosidase digestion
based carbohydrate sequencing. The relative peak areas of the identi-
fied N-glycans were used in a comparative quantitative evaluation to
find a potential preliminary glycobiomarker panel to differentiate lung
cancer, COPD and their comorbidity from each other and from the
control.
2. Materials and methods
2.1. Chemicals and reagents
Water (HPLC grade), acetonitrile, sodium cyanoborohydride (1 M in
THF), glycerol, ribonuclease B, immunoglobulin G, α-1-antitrypsin and
DTT (dithiothreitol) were obtained from Sigma Aldrich (St. Louis, MO,
USA). SDS (sodium dodecyl sulfate) and Nonidet P-40 were from VWR
(Radnor, PA, USA). The Fast Glycan Labeling and Analysis Kit was from
SCIEX (Brea, CA, USA) including the bracketing standards of maltose
(DP2) and maltopentadecaose (DP15). The exoglycosidase enzymes of
Sialidase A (Arthrobacter ureafaciens), β-Galactosidase (Jack bean) and
β-N-Acetyl Hexosaminidase (Jack bean) were from ProZyme (Hayward,
CA, USA). The endoglycosidase PNGase F was from Asparia Glycomics,
(San Sebastian, Spain).
2.2. Sample preparation
All serum samples were collected with the appropriate Ethical
Permissions (approval number: 23580-1/2015/EKU (0180/15)) and
Informed Patient Consents at the Department of Pulmonology in the
Semmelweis Hospital (Miskolc, Hungary). For this pilot study, the
samples were pooled in order to efficiently determine all possible
glycan structures in the pooled samples [26]. Serum samples from 90
healthy individuals (control), 90 lung cancer patients, 90 COPD pa-
tients and 90 patients with comorbidity of COPD with lung cancer were
separately pooled.
Preparation of human serum samples included denaturation, glycan
release, fluorophore labeling and magnetic bead mediated cleanup.
First, 2 µL of serum samples were diluted with HPLC grade water to
10 µL. Since the Fast Glycan Sample Preparation and Analysis protocol
was optimized for purified IgG samples, to avoid possible precipitation
issues with the more complex serum samples, a modified denaturation
protocol was used by adding 5 µL denaturation solution and applying
40 °C for 10 min followed by 70 °C for 10 min. The glycan release
process was also modified and performed with the addition of 1.0 µL of
PNGase F enzyme (200 mU) to the reaction mixture and incubated at
60 °C for 1 h instead of 20 min, to ensure complete removal of the
serum N-glycome. The endoglycosidase digestion reaction was stopped
by the addition of 120 µL of ice-cold acetonitrile to precipitate
all remaining protein/polypeptide content. This was followed by
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centrifugation for 5 min at 13,500 RPM (BioSan, Biocenter Ltd,
Hungary). The supernatant that contained all released sugars was dried
under reduced pressure at 60 °C for 1 h in a SpeedVac (Jouan RC 10.10
Vacuum Concentrator Centrifugal System, Jouan, San Fransisco, CA,
USA). The dry samples were reconstituted in the labeling solution
containing 4.0 µL of 40 mM 8-aminopyrene-1,3,6-trisulfonic acid
(APTS) in 20% acetic acid, 2.0 µL of NaBH3CN (1 M in THF) and 4 µL
20% acetic acid. The reaction mixture was incubated in a heating block
using a modified evaporative labeling protocol with closed vial cap at
50 °C for 60 min, followed with open cap at 55 °C for 80 min [27]. The
labeling reagent was added in great excess to avoid competition with
any possible remaining amine containing molecules. After the labeling
step, the samples were purified by magnetic beads following the Fast
Glycan Sample Preparation and Analysis protocol and analyzed by CE-
LIF. Exoglycosidase digestions were performed by consecutive addi-
tions of sialidase A to remove all α 2-3,6,8-linked sialic acids, Jack bean
galactosidase to remove β1-4,6-linked galactose residues and Jack bean
hexosaminidase to remove the β1-2,4,6-linked N-acetyl-glucosamines
by respective overnight incubations at 37 °C as described earlier in
[28].
2.3. Capillary electrophoresis
Capillary electrophoresis analyses with laser induced fluorescent
detection (CE-LIF) were performed using a PA800 Plus Pharmaceutical
Analysis System (SCIEX). All CE measurements were accomplished in
40 cm effective length (50 cm total length), 50 µm ID bare fused silica
capillaries filled with the HR-NCHO separation gel buffer (SCIEX).
30 kV electric potential was applied during the separation steps in re-
versed polarity mode (cathode at the injection side, anode at the de-
tection side) at 30 °C. To increase detection sensitivity and reproduci-
bility, a three-stage sample injection procedure was used: Step 1) 1.0 psi
for 5.0 sec water pre-injection, Step 2) 3.0 kV for 3.0 sec sample in-
jection and Step 3) 2.0 kV for 2.0 sec bracketing standard injection. This
latter was used for high precision GU value determination by the GUcal
software (www.GUcal.hu) [29]. Data collection and analysis were im-
plemented by the 32Karat (version 10.1) software package (SCIEX).
Relative percentage area values of the separated peaks were calculated
by the PeakFit v4.12 Software (SeaSolve Software Inc., San Jose, CA).
3. Results and discussion
In this pilot study, a new and improved sample preparation method
was applied to accommodate the high complexity of the human serum
samples including temperature adjusted denaturation, extended glycan
release and evaporative labeling protocol. Capillary electrophoresis -
laser induced fluorescence detection was used to analyze and compare
the N-glycosylation patterns of pooled human serum samples from 90
patients each with chronic obstructive pulmonary disease (COPD), lung
cancer (LC), and their comorbidity (COPD with LC) to healthy in-
dividuals (as control). The inter- and intraday variability of the opti-
mized method were under 3.5% for the pooled human serum samples.
For better comparability and consequently easier structural identifica-
tion, the timescale of the acquired electropherograms were converted
from migration time to GU values using the GUcal software (freely
available from GUcal.hu) [29]. A representative electropherogram of
the pooled healthy human serum sample N-glycome is shown in Fig. 1,
featuring the separation of 61 peaks. Structural elucidation of all se-
parated N-glycans utilized direct mining of GU database entries (Gly-
coStore.org), exoglycosidase digestion based carbohydrate sequencing
[28], comparison to oligosaccharides released from carefully chosen
glycoprotein standards (ribonuclease B, immunoglobulin G, α-1-anti-
trypsin), and some earlier published literature data on the same subject
matter [30–32]. The exoglycosidase based glycan sequencing process is
shown in Fig. 2, utilizing sialidase A, galactosidase and hex-
osaminidase, depicted by the corresponding traces. Sequence
information was derived from the GU value shifts of the individual
peaks as the result of the consecutive exoglycosidase treatments [33].
Table 1 lists all identified N-glycan structures in the pooled human
serum sample as numbered in Fig. 1. The first level of structural elu-
cidation of the separated glycans accomplished by using their GU va-
lues to search the GlycoStore database (glycostore.org). Glycans de-
noted by # were identified considering the results of the sequential
exoglycosidase digestion process shown in Fig. 2. Structure identifica-
tion of entries marked with asterisks were accomplished based on a
comparative exercise utilizing the N-glycan profiles of IgG (*), RNase B
(**) and AAT (***) [32,34,35]. It is important to note that besides these
61 carbohydrates, no other glycan structures were detected in the pa-
thological samples compared to the control.
After the identification of the separated N-glycan structures in the
pooled healthy human control serum sample, the relative peak areas of
all peaks were computed and quantitatively compared to lung cancer,
COPD and their comorbidity (COPD with LC) pooled sample data with
their respective SD values based on the triplicate runs. Before the in-
tegration step for peak area determination, all electropherograms were
normalized to peak 61 (FA2BG2), i.e., the RFU values were divided by
the RFU value of peak 61, because it was apparently stable in size in all
runs and well-separated from the other peaks. This normalization step
was necessary to adequately calculate the peak areas of some of the not
completely separated peaks. After the normalization step, the relative
peak area % values were calculated by dividing the integrated peak
areas by the sum of all integrated areas and multiplied by 100. Table 1
lists the suggested glycan structures corresponding to the separated
peaks in Fig. 1, the calculated CE-LIF GU values and relative peak areas
with their SDs. Only peaks with> 1% relative peak areas were taken
into consideration in this comparative pilot study (highlighted bold in
Table 1). All runs were done in triplicates and the average RSD of the
relative peak areas was 3.46%. Please note that rows 62–78 in Table 1
represent the peaks appeared during exoglycosidase digestion after
each sequential analysis step.
Changes in relative peak areas of the pooled lung cancer, COPD and
comorbidity (COPD with LC) samples were compared to the pooled
healthy control, based on their capillary electrophoresis analysis re-
sults. As shown in Table 2, only glycans with significant alterations
were taken into consideration during the evaluation process, i.e., N-
glycan structures satisfying the following two criteria: 1) the relative
peak areas of the N-linked glycan structures were>1%, at least in one
sample group of healthy control, COPD, lung cancer, or their co-
morbidity (bold structures in Table 1); and 2) at least one of the ob-
served relative peak area differences between any of the disease groups
and the control was> 33%.
As one can observe, several relative peak area values in the pooled
LC sample were considerably altered compared to the control (Table 2,
Column 3), such as FA4BG4[3,3,3,3]S4 (peak 5: +167% ± 7.4),
FA3G3[6]S3 (peak 7: +176% ± 9.7), A2BG2S2 + M3 (peaks 9–10:
+133% ± 6.3), FA2G2S2 (peak 11: 105% ± 5.1), FA2BG2S2 (peak
12: 50% ± 2.9), A2BG2S1 (peak 28: −33% ± 1.6), FA2G2S1 (peak
29: −41% ± 2.1), FA2BG2S1 (peak 32: −41% ± 2.1), A2B (peak 35:
+36% ± 2.1) and FA2G2 (peak 59: −36% ± 1.7). These changes
may have diagnostic glycobiomarker potential for lung cancer. On the
other hand, one should take into consideration that the following re-
lative peak areas also increased in COPD: FA4BG4[3,3,3,3]S4 (peak 5,
LC:+167% ± 7.4, COPD: +106% ± 5.2), A2BG2S2 + M3 (peaks
9–10, LC:+133% ± 6.3, COPD: +58% ± 2.8) and FA2BG2S2 (peak
12, LC:+50% ± 2.9, COPD: +33% ± 1.8), therefore, they may in-
dicate the presence of both lung cancer or COPD, but not the co-
morbidity. In addition the increment of the relative peak area of
FA3G3[6]S3 (peak 7, LC:+176% ± 9.7, COPD: +79% ± 3.8, LC
with COPD: +56% ± 3.0) could represent either lung cancer or COPD
or their comorbidity. Interestingly, peak 28, corresponding to the
A2BG2S1 structure slightly increased (+12% ± 0.6) in comparison of
COPD to control, while significantly decreased (−33% ± 1.6) in lung
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Fig. 1. Capillary electrophoresis analysis of the released and APTS labeled N-glycans from pooled healthy human serum (upper panel). The lower panels show the
enlarged sections of the electropherogram: A) GU 4.3–5.2; B) GU 5.2–6.4; C) GU 6.4–8.1; and D) GU 8.0–10.7. The corresponding structures, GU values and relative
peak areas with their SD are listed in Table 1. Separation conditions: 40 cm effective capillary length (50 cm total length), 50 μm ID bare fused silica; 30 kV (0.17 min
ramp time) separation voltage in reversed polarity mode. LIF detection (excitation: 488 nm/emission: 520 nm); separation temperature 30 °C. Injection: water pre-
injection 5.0 s at 1.0 psi, followed by 3.0 kV/3.0 s sample and 2.0 kV/2.0 s bracketing standard (DP2 + DP15).
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cancer compared to control, therefore could also be a glycobiomarker
for lung cancer. Moreover, using Column 4 in Table 2, one can distin-
guish COPD from lung cancer considering the increasing changes in
FA3G3[6]S3, A2BG2S2 + M3, FA2G2S2, A2B and FA2 + M6
(54% ± 2.5, 47% ± 2.2, 79% ± 4.2, 35% ± 2.0 and 41% ± 2.1),
and the decreasing values of A2BG2S1 and FA2G2S1 (41% ± 1.9 and
39% ± 2.0).
In addition, the relative peak area change of peak 29 (FA2G2S1)
may discern comorbidity of COPD with lung cancer (−37% ± 1.7)
from COPD (−4% ± 0.2), but not from lung cancer (−41% ± 2.1).
In all pathological samples peak 59 (FA2G2, LC: −36% ± 1.7, COPD:
−34% ± 1.6, LC with COPD: −39% ± 2.1) decreased, thus, possibly
distinguish them only from the control. Please note that FA2 + M6
(peaks 38–39) and A2BG2S2 + M3 (peaks 9–10) structures were co-
migrating, thus their individual alterations could not be precisesly
evaluated.
Fig. 3 shows the quantitative alterations among the relative peak
areas within the N-glycan subclasses specified by branching, degrees of
sialylation and total fucosylation, determined in the control, COPD,
lung cancer and comorbidity of COPD with lung cancer patient serum
samples. Variations in the size of the carbohydrate structures were
evaluated based on their degree of branching, i.e., the amounts of
various mono-, bi-, tri-, and tetra-antennary types. The number of
Fig. 2. Exoglycosidase digestion based carbohydrate sequencing of the pooled
healthy human control serum N-glycome using sialidase ( ), galactosidase
( ), and hexosaminidase ( ) to verify the identity of the glycan structures of
interest. Separations conditions were the same as in Fig. 1. The corresponding
structures and GU values are listed in Table 1.
Table 1
The identified N-glycan structures in the pooled healthy control human serum sample, their CE-LIF GU values and relative peak areas with SD. Bold entries represent
peaks with>1% relative peak areas (at least in one sample groups from the control, COPD, LC and LC with COPD). Entries from 62 to 78 depict the glycan structures
of the sequencing analysis results (shown in Fig. 2). Abbreviated structure names followed the nomenclature suggested in [36]. Entries were identified as follows: 1)
based on their GU values using the GlycoStore database (glycostore.org); 2) considering the results of the sequential exoglycosidase digestion experiments shown in
Fig. 2 (denoted with #) and 3) all other glycan structures were identified based on N-glycosylation information of high abundant glycoproteins in serum: IgG (*),
RNase B (**) and AAT (***).
N-glycan structure GU Relative peak area (%) N-glycan structure GU Relative peak area (%)
1 A4G4[3,3,3,6]S4# 4.4 0.0955 ± 0.003 40 M6** 7.8 0.8338 ± 0.039
2 A4G4[3,3,3,3]S4# 4.46 0.0935 ± 0.002 41 A3G3[3]S1# 7.89 0.5296 ± 0.013
3 A1G1S1# 4.51 0.1307 ± 0.006 42 FA3# 7.98 0.4379 ± 0.011
4 FA4G4[3,3,3,6]S4*** 4.57 0.1285 ± 0.004 43 A2B[6]G1 8.08 0.2962 ± 0.009
5 FA4BG4[3,3,3,3]S4# 4.62 0.6814 ± 0.015 44 FA2B* 8.2 1.9016 ± 0.064
6 A2G2[6]S2* 4.71 21.8425 ± 0.953 45 A2B[3]G1* 8.35 0.6615 ± 0.026
7 FA3G3[6]S3# 4.77 0.9032 ± 0.026 46 M7** 8.48 0.3190 ± 0.014
8 A2G2[3]S2*** 4.88 2.4776 ± 0.098 47 M7** 8.62 0.3836 ± 0.013
9 A2BG2S2* 4.93 1.5508 ± 0.038 48 FA2[6]G1* 8.75 6.1207 ± 0.293
10 M3 49 M7**
11 FA2G2S2* 4.97 2.3546 ± 0.052 50 FA2[3]G1* 9.09 2.9771 ± 0.134
12 FA2BG2S2* 5.1 1.2156 ± 0.026 51 FA2B[6]G1* 9.17 2.5049 ± 0.067
13 FA3G3[3]S3*** 5.14 1.2645 ± 0.031 52 M8**
14 A2[6]G1S1* 5.24 0.1604 ± 0.007 53 A4G4[6]S1 9.34 0.1668 ± 0.008
15 A2[3]G1[6]S1 5.3 0.1631 ± 0.005 54 A4G4[3]S1 9.48 0.1636 ± 0.004
16 FA3BG3S3# 5.39 0.5907 ± 0.026 55 FA2B[3]G1* 9.55 0.4411 ± 0.012
17 A4G4[6]S3 5.47 0.8155 ± 0.040 56 M8** 9.64 0.5983 ± 0.023
18 A2[3]G1[3]S1* 5.56 0.2984 ± 0.012 57 M8** 9.73 0.3001 ± 0.009
19 FA2G2[6]S2*** 5.66 0.3043 ± 0.018 58 FA4*** 9.86 0.0874± 0.004
20 A3G3[6]S2 5.72 1.1683 ± 0.031 59 FA2G2* 10.14 3.5100 ± 0.089
21 FA2[6] G1S1* 5.83 0.7706 ± 0.029 60 M9** 10.25 0.9882 ± 0.042
22 A4G4[3,3,3]S3 5.95 0.9457 ± 0.024 61 FA2BG2* 10.52 0.8847 ± 0.035
23 FA2[3]G1S1* 6.03 0.5180 ± 0.017 62 A1G1 6.62 Sequencing
24 A3G3[3]S2 6.17 0.8196 ± 0.030 63 A2[3]G1 8.12 Sequencing
25 A2G2[6]S1* 6.28 13.1137 ± 0.465 64 A2G2 9.17 Sequencing
26 FA2B[6]G1S1* 6.48 0.4828 ± 0.016 65 A2BG2 10 Sequencing
27 FA2B[3]G1S1* 66 A3[6]G3 11.36 Sequencing
28 A2BG2S1* 6.58 1.3189 ± 0.034 67 A3[3]G3 11.63 Sequencing
29 FA2G2S1* 6.76 4.1359 ± 0.095 68 FA3G3 12.33 Sequencing
30 A2* 6.82 2.7863 ± 0.119 69 FA3BG3 12.54 Sequencing
31 M5** 70 A4G4 13.72 Sequencing
32 FA2BG2S1* 6.94 2.2966 ± 0.063 71 FA4G4 14.38 Sequencing
33 A4G4[6]S2 7.05 1.3916 ± 0.049 72 FA4BG4 14.45 Sequencing
34 A4G4[3]S2 7.17 0.5179 ± 0.023 73 A1 5.86 Sequencing
35 A2B* 7.27 0.7528 ± 0.023 74 A3 7.81 Sequencing
36 A2[6]G1 7.4 0.1440 ± 0.004 75 A4 8.94 Sequencing
37 A3G3[6]S1 7.51 0.1470 ± 0.005 76 FA3B 9.93 Sequencing
38 FA2* 7.67 9.5132 ± 0.270 77 FA4B 11.02 Sequencing
39 M6** 78 FM3 5.09 Sequencing
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terminal sialic acids was also taken into consideration in the evaluation
process, focusing on the tendency of the relative peak area changes in
mono-, bi-, tri- and tetra-sialylation. The relative peak areas of mono-
sialylated glycans slightly increased in COPD (+5% ± 0.2), slightly
decreased in comorbidity of COPD with lung cancer (−6% ± 0.2) and
more substantially decreased in lung cancer (−27% ± 0.9). Moreover,
the relative peak areas of bi-, tri- and tetrasialylated subclasses variably
increased in COPD, lung cancer and their comorbidity (COPD with LC)
in comparison to the pooled control healthy human serum and the in-
crement was the highest in lung cancer (bi-sialylated: +12% ± 0.4,
tri-sialylated: +42% ± 1.4, tetra-sialylated: +168% ± 5.8), medium
in COPD (bi-sialylated: +7% ± 0.2, tri-sialylated: +16% ± 0.6,
tetra-sialylated: +117% ± 4.1) and the smallest in their comorbidity
(bi-sialylated: +6% ± 0.2, tri-sialylated: +8% ± 0.3, tetra-sialy-
lated: +23% ± 0.8). The relative peak areas of fucosylated N-glycans
slightly decreased in COPD (−8% ± 0.3) and also in comorbidity of
COPD with lung cancer (−4% ± 0.1) in contrast to lung cancer, where
a small increase (+7% ± 0.2) was observed.
The relative peak areas of mono-, tri- and tetra-antennary glycans
similarly to the bi-, tri- and tetra-sialylated subclasses increased in all
three disease groups compared to the healthy control with the highest
increment in lung cancer (mono-antennary: +116% ± 4.0, tri-an-
tennary: +45% ± 1.6, tetra-antennary: 44.5% ± 1.5), medium in
COPD (mono-antennary: +59% ± 2.0, tri-antennary: +15% ± 0.5,
tetra-antennary: 31% ± 1.1) and the smallest in their comorbidity
(mono-antennary: +30% ± 1.0, tri-antennary: +7.5% ± 0.3, tetra-
antennary: 3% ± 0.1). In contrary, the relative peak areas of bi-an-
tennary N-glycans hardly decreased or not changed at all in all sample
types of COPD (−3% ± 0.1), lung cancer (−5% ± 0.2) and co-
morbidity of COPD with lung cancer (−0.3% ± 0.0) compared to the
control. However, taking a closer look at the data, these observed
changes were apparently caused by the interplay between various in-
creasing and decreasing amounts of bi-antennary structures, i.e., the
relative peak areas of some bi-antennary glycans significantly decreased
(e.g., A2BG2S1 (peak 28): LC: −33% ± 1.6, LC with COPD:
−17% ± 1.0; FA2G2S1 (peak 29): LC: −41% ± 2.1, COPD:
−4% ± 0.2, LC with COPD: −37% ± 1.7; FA2G2 (peak 59): LC:
−36% ± 1.7, COPD: −34% ± 1.6, LC with COPD: −39% ± 2.1);
while others increased (e.g., A2BG2S2 + M3) (peaks 9–10): LC:
+133% ± 6.3, COPD: +58% ± 2.8, LC with COPD: +29% ± 1.4;
FA2G2S2 (peak 11): LC: +105% ± 5.1, COPD: +15% ± 0.7, LC with
COPD: +4% ± 0.2; FA2BG2S2 (peak 12): LC: +50% ± 2.9, COPD:
+33% ± 1.8, LC with COPD: +16% ± 0.7 and A2B (peak 35): LC:
+36% ± 2.1, LC with COPD: +12% ± 0.6), thus their changes were
almost counterbalanced. Based on these observations, as a first ap-
proximation we considered that N-glycan subclasses of mono- tri- and
tetrasialylated, fucosylated as well as mono-, tri- and tetra-antennary
forms could serve as potential biomarkers for lung cancer, COPD and
their comorbidity.
4. Conclusion
In this pilot study, the N-glycosylation profiles of patient samples of
chronic inflammatory (COPD) and malignant (LC) pulmonary diseases
as well as their comorbidity (COPD with LC) were quantitatively stu-
died and compared to healthy controls to get a better insight about the
glycan structures/ratios, which can be expected in each pool. A novel
temperature adjusted denaturation protocol as well as extended enzy-
matic release and evaporative derivatization time was used for the as-
paragine linked oligosaccharides from the complex serum samples,
which were then analyzed by capillary electrophoresis with high sen-
sitivity laser induced fluorescence detection. Sixty-one N-glycan struc-
tures were identified in the control human serum samples and since no
other glycans appeared in any of the three disease categories, these 61
structures were quantitatively monitored in this study. Our results
suggested that certain serum N-glycans could be used as potential
markers for the different types of pulmonary diseases. Therefore, the
panel of the 13 glycans listed in Table 2 could be considered to dif-
ferentiate lung cancer, COPD and their comorbidity from the control as
well as LC from COPD. In addition, alterations in the N-glycan sub-
classes, such as fucosylated, mono-, bi-, tri- and tetra-sialylo, as well as
mono-, bi-, tri- and tetra-antennary glycans could also carry interesting
diagnostic information. The glycan panel in Table 2 and the corre-
sponding subclasses may provide even more reliable information as
they represent the sum of multiple structural changes caused by a given
Table 2
Comparison of the relative peak areas of lung cancer (LC), COPD, their comorbidity (COPD with LC) to the control sample and between LC and COPD along with their
SD, where at least one observed difference was> 33% (bold numbers) for any peak with>1% relative area between the disease and control samples.
Peak Number N-Glycan structure LC to Control % COPD to Control % LC + COPD to Control % LC to COPD %
5 FA4BG4[3,3,3,3]S4 167 ± 7.4 106 ± 5.2 18 ± 0.9 29 ± 1.4
7 FA3G3[6]S3 176 ± 9.7 79 ± 3.8 56 ± 3.0 54 ± 2.5
9–10 A2BG2S2, M3 133 ± 6.3 58 ± 2.8 29 ± 1.4 47 ± 2.2
11 FA2G2S2 105 ± 5.1 15 ± 0.7 4 ± 0.2 79 ± 4.2
12 FA2BG2S2 50 ± 2.9 33 ± 1.8 16 ± 0.7 13 ± 0.9
28 A2BG2S1 −33 ± 1.6 12 ± 0.6 −17 ± 1.0 −41 ± 1.9
29 FA2G2S1 −41 ± 2.1 −4 ± 0.2 −37 ± 1.7 −39 ± 2.0
32 FA2BG2S1 −41 ± 2.1 −30 ± 1.5 −26 ± 1.3 −17 ± 0.8
35 A2B 36 ± 2.1 0 ± 0 12 ± 0.6 35 ± 2.0
38–39 FA2, M6 15 ± 0.9 −18 ± 0.9 28 ± 1.6 41 ± 2.1
59 FA2G2 −36 ± 1.7 −34 ± 1.6 −39 ± 2.1 −3 ± 0.1
Fig. 3. Alterations among the relative peak areas of specific N-glycan subclasses
(Sialoforms: mono-, bi-, tri- and tetra-sialo; Fucosylated and Branching: mono-,
bi- tri- and tetra-antennary) of lung cancer (black), COPD (gray) and their co-
morbidity (dark gray) with their corresponding RSDs. The results were calcu-
lated based on the data in supplementary Table 1.
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disease. This is especially applicable for the highly branched sialylated
structures as our recent genotyping data suggested significant increase
of MGAT5 activity, i.e., increased branching in lung cancer [37]. Cur-
rently we are in the process of collecting 300 samples from each disease
groups that will be individually analyzed in view of our preliminary
pooled sample based results.
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